Table 2.
The new five-group comprehensive cytogenetic prognostic system for MDS developed by Schanz et al. (Adapted from reference 48••)
| Prognostic Subgroup (% of patients) | Very Good (2.9 %) | Good (65.9 %) | Intermediate (20.7 %) | Poor (3.6 %) | Very Poor (7.0 %) |
|---|---|---|---|---|---|
| Cytogenetic abnormality | |||||
| Single | -Y | Normal | 7q- | inv(3) | NA |
| 11q- | 5q- | +8 | t(3q) | ||
| 12p- | i(17q) | 3q- | |||
| 20q- | +19 | −7 | |||
| Any other | |||||
| Double | NA | Including 5q- | Any other | Including −7 or 7q- | NA |
| Complex | NA | NA | NA | 3 | > 3 |
| Outcomes | |||||
| Median OS (months) (95 %CI) | 60.8 (50.3 – NR) | 48.6 (44.6 – 54.3) | 26.0 (22.1 – 31.0) | 15.8 (12.0 – 18.0) | 5.9 (4.9 – 6.9) |
| HR for OS (95 %CI) | 0.5 (0.3 – 0.7) | 1.0 (0.98 – 1.1) | 1.6 (1.4 – 1.8) | 2.6 (2.1 – 3.2) | 4.2 (3.4 – 5.2) |
| Median time to leukemic progression (months) (95 %CI) | NR (121.2 – NR) | NR (189.0 – NR) | 78.0 (42.6 – NR) | 21.0 (13.4 – 42.2) | 8.2 (6.4 – 15.4) |
| HR for leukemic progression (95 %CI) | 0.5 (0.2 – 1.2) | 1.0 (0.9 – 1.2) | 2.2 (1.8 – 2.7) | 3.4 (2.5 – 4.6) | 4.9 (3.6 – 6.7) |
NA: Not available, OS: Overall survival, CI: Confidence interval, HR: Hazard ratio, NR: Not reached